Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Dr. Wassil Nowicky — Dipl. Ing., Dr. techn., DDDr. h. c., Director of “Nowicky Pharma” and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). Has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to “Diplomingeniueur” in 1960 which title was nostrificated in Austria in 1975. Dr. Wassil Nowicky became the very first scientist in the development of the anticancer protonic therapy and is the inventor of the preparation against cancer with a selective effect on basis of celandine alkaloids “NSC-631570”. He used the factor that cancer cells are more negative charged than normal cells and invented the Celandine alkaloid with a positive charge thanks to which it accumulates in cancer cells very fast. Thus, Dr. Nowicky is invited as an Honorable Speaker to take part in many scientific international congresses and conferences in USA, Australia, Japan, UAE, Europe. Author of over 300 scientific articles dedicated to cancer research. Dr. Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name od Albert Schweizer. He has received the award for merits of National guild of pharmasists of America. the award of Austrian Society of sanitary, hygiene and public health services and others.
Clinical efficacy of NSC?631570 is not coincidental or even ‘spontaneous remission’ but rather a consequence of its mechanisms of action confirmed in various in vitro and in vivo studies. NSC?631570 has been tested on more than 100 cancer cell lines so far. Among others, NSC?631570 was tested at the National Cancer Institute (Bethesda, Maryland, USA) on 60 cell lines representing eight important human malignant tumors: brain tumors, ovarian, small cell and non?small lung cancer, colon cancer, kidney cancer, leukaemia and malignant melanoma. NSC?631570 exerted toxic effects against all these cell lines. Compared to 5?fluorouracil (5?FU) and gemcitabine, two standard cytotoxic agents in the treatment of digestive tract tumors, NSC?631570 achieved better results and not only inhibited the cell growth but reduced the cell mass, also. In 1998, a group around Anne Panzer (University of Pretoria, South Africa) proved the selective effect of NSC?631570 on molecular level. Tests on human cervical carcinoma cells HeLa, squamous cell carcinoma WHCO5 and normal equine lung cell lines demonstrated that NSC?631570 is selectively toxic against cancer cells. It causes a metaphase block which is characterized by an abnormal distribution of chromosomes and the formation of micronuclei and results in apoptosis. Normal cells are not influenced in the process. NSC?631570 was effective in the therapy of recurring lung diseases in children from the Chernobyl area.